View metadata, citation and similar papers at core.ac.uk

brought to you by CORE

provided by KITopen

Regulation of the pleiotropic effects of tissue-resident mast cells

Michael Huber, PhD,[a] Andrew C. B. Cato, PhD,[b] George K. Ainooson, PhD,[b] Marc Freichel, MD,[c] Volodymyr Tsvilovskyy, PhD,[c] Rolf Jessberger, PhD,[d] Eva Riedlinger, Cand. Med.,[e] Christian P. Sommerhoff, MD,[e] and Stephan C. Bischoff, MD[f] *Aachen, Eggenstein-Leopoldshafen, Heidelberg, Dresden, Munich, and Stuttgart, Germany*

Mast cells (MCs), which are best known for their detrimental role in patients with allergic diseases, act in a diverse array of physiologic and pathologic functions made possible by the plurality of MC types. Their various developmental avenues and distinct sensitivity to (micro-) environmental conditions convey extensive heterogeneity, resulting in diverse functions. We briefly summarize this heterogeneity, elaborate on molecular determinants that allow MCs to communicate with their environment to fulfill their tasks, discuss the protease repertoire stored in secretory lysosomes, and consider different aspects of MC signaling. Furthermore, we describe key MC governance mechanisms (ie, the high-affinity receptor for IgE [FcεRI]), the stem cell factor receptor KIT, the IL-4 system, and both Ca^{2+}-and phosphatase-dependent mechanisms. Finally, we focus on distinct physiologic functions, such as chemotaxis, phagocytosis, host defense, and the regulation of MC functions at the mucosal barriers of the lung, gastrointestinal tract, and skin. A deeper knowledge of the pleiotropic functions of MC mediators, as well as the molecular processes of MC regulation and communication, should enable us to promote beneficial MC traits in physiology and suppress detrimental MC functions in patients with disease. (J Allergy Clin Immunol 2019;144:S31-45.)

***Key words:** FcεRI, stem cell factor, IL-4, calcium signaling, phosphatases, chemotaxis, tryptase, chymase, integrins, Toll-like receptors, ion channels*

Abbreviations used

BM:	Bone marrow
CPA3:	Carboxypeptidase A3
CRAC:	Ca^{2+} release–activated Ca^{2+}
CTMC:	Connective tissue mast cell
DUSP:	Dual-specificity phosphatase
ERK:	Extracellular signal-regulated kinase
GPCR:	G protein–coupled receptor
HSC:	Hematopoietic stem cell
IP_3:	Inositol-1,4,5-trisphosphate
MAPK:	Mitogen-activated protein kinase
MC:	Mast cell
MC_C:	Mast cell expressing only chymase
MCp:	Mast cell precursor
MC_T:	Mast cell expressing only tryptase
MC_{TC}:	Mast cell expressing tryptase and chymase
MMC:	Mucosal mast cell
mMCP:	Mouse mast cell protease
MyD88:	Myeloid differentiation response gene–88
PEP:	PEST domain–enriched tyrosine phosphatase
PLC:	Phospholipase C
PMC:	Peritoneal mast cell
SCF:	Stem cell factor
SOCE:	Store-operated Ca^{2+} entry
S1P:	Sphingosine-1-phosphate
TLR:	Toll-like receptor
TRIF:	TIR domain-containing adapter inducing IFN-β
TRP:	Transient receptor potential
TULA-2:	T-cell ubiquitin ligand 2

HETEROGENEITY OF MAST CELLS

The term mast cell (MC) describes a highly heterogeneous cell population. Numerous MC subtypes have now been characterized in both human subjects and animals based on differences in cell morphology, histochemical properties, protease content in granules, piecemeal or anaphylactic types of degranulation, receptor expression, and function.[1,2] A certain subtype plasticity has been recognized depending on the tissue environment, and *in vitro* MCs change their phenotype depending on culture conditions.[3-5]

From [a]the Institute of Biochemistry and Molecular Immunology, Medical Faculty, RWTH Aachen University; [b]the Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, Eggenstein-Leopoldshafen; [c]the Institute of Pharmacology, Heidelberg University, Medical Faculty, Heidelberg; [d]the Institute for Physiological Chemistry, Medical Faculty Carl Gustav Carus, Technische Universität Dresden; [e]the Institute of Laboratory Medicine, University Hospital, LMU Munich; and [f]the Institute of Nutritional Medicine, University of Hohenheim, Stuttgart.

This article was published as part of a supplement sponsored by the members of the Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease.

Supported in part by the Deutsche Forschungsgemeinschaft Priority Programme 1394 ("Mast cells—promoters of health and modulators of disease"; to M.H., A.C.B.C., M.F., R.J., C.P.S., and S.C.B.). Further support was granted by TR-SFB 152 (to M.F.). A.C.B.C. acknowledges the help of V. Gourain, NGS Facility of the Institute of Toxicology and Genetics (KIT; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108972).

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication April 13, 2018; revised January 29, 2019; accepted for publication February 1, 2019.

Available online February 15, 2019.

Corresponding authors: Michael Huber, PhD, Institute of Biochemistry and Molecular Immunology, RWTH Aachen University, Pauwelsstr 30, D-52074 Aachen, Germany. E-mail: mhuber@ukaachen.de. Or: Stephan C. Bischoff, MD, Institute of Nutritional Medicine, University of Hohenheim, Fruwirthstr 12, D-70599 Stuttgart, Germany. E-mail: bischoff.stephan@uni-hohenheim.de.



The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749

© 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.jaci.2019.02.004

In addition to intraspecies heterogeneity, interspecies heterogeneity has been discovered.[6] This is of relevance because a large part of the scientific literature on MCs is based on animal work, in particular mouse studies. Data on human MCs are scarce because they are difficult to collect from tissue sources. Therefore many laboratories use genetically transformed human MC lines instead of primary MCs from tissue or immature MCs derived from bone marrow (BM) or peripheral blood that are partially maturated under particular culture conditions. Although it is well known that such MCs differ functionally from primary tissue MCs, they have nonetheless provided useful insights into the regulation and function of human MCs.

MC subtypes in human subjects

Human MCs can be characterized according to the types of proteases they contain, such as mast cells expressing tryptase and chymase (MC_{TC}s), mast cells expressing only tryptase (MC_Ts), and the rare mast cells expressing only chymase (MC_Cs). MC_{TC}s are located at nonmucosal sites (in the skin, the submucosa, adjacent to blood vessels, and in the peritoneum in mice), whereas MC_Ts are primarily found at mucosal sites (nose, lung, and intestine).

Further division of these subtypes into site-specific populations has been proposed to reflect the microenvironment of the anatomic compartments where they are localized, such as "lung MC_T" to reflect prevalence in the bronchi, bronchioles, and alveolar parenchyma and "MC_{TC}" to denote abundance in pulmonary vessels and the pleura. Within each MC_{TC} and MC_T population, there are also distinct localization-specific expression patterns of receptors, enzymes, and growth factors that can be used for further characterization. For instance, bronchial MC_Ts consistently express more histidine decarboxylase than alveolar MC_Ts, whereas for both MC_{TC}s and MC_Ts, the high-affinity receptor for IgE (FcεRI) is highly expressed in conducting airways but virtually absent in alveolar parenchyma.[7] It is not only the tissue site but also the disease status that influences MC heterogeneity. In patients with poorly controlled, severe, T_H2-associated asthma, an altered subtype that could play a role in the pathophysiology of this disease[8] has been described to express tryptase, chymase, and/or carboxypeptidase A3 (CPA3). Genetic analyses have revealed even more heterogeneity among MCs from different sites within one tissue, although the clinical implications are yet unclear.[9]

MC subtypes in rodents

In mice and rats MCs are traditionally subtyped into connective tissue mast cells (CTMCs) and mucosal mast cells (MMCs) based on their histochemical properties, mediator content, and functional properties.[10] CTMCs can be stained with both Alcian blue and safranin, whereas MMCs can only be stained with Alcian blue. In terms of their mediator content, heparin proteoglycans predominate in CTMCs, whereas chondroitin sulfate predominates in MMCs. In their functional properties CTMCs typically contain rodent tryptases, chymases, and CPA3, whereas MMCs contain chymases only and thus differ fundamentally from their human counterparts in mucosal tissues that contain tryptase only. The subtyping of murine MCs into CTMCs and MMCs might be an oversimplification for the mouse intestine and peritoneum but not for the lung.[11]

REGULATION OF MC DEVELOPMENT

Development of MCs can be subdivided into 3 major steps: differentiation of hematopoietic stem cells (HSCs) to mast cell precursors (MCps) in the BM, distribution of MCps through blood and transendothelial migration into target tissues, and eventually phenotypic maturation in different tissues. Although there are still certain discrepancies concerning our understanding of MCp development in the BM, it is justified to suggest that committed MCps stem from bipotent progenitors endowed with the capacity to differentiate into both MCs and basophils, as has been studied in mice.[12]

Expression of the receptor tyrosine kinase KIT for MC development is mandatory. Likewise, expression of the KIT ligand stem cell factor (SCF) is obligatory for MC development *in vivo*. Mature MCs are usually characterized by their expression of KIT and FcεRI, as well as distinct metachromatic cytoplasmic granules. MCps do not necessarily express FcεRI and are typically not identifiable by means of metachromatic staining, indicating that commitment to the MC lineage occurs before FcεRI expression. Indeed, early committed MCps lack FcεRI expression but show KIT expression.[13] Hence MCps ready to leave the BM can be either FcεRI positive or FcεRI negative. Less is known about committed MCps in human subjects, although an immature human MCp population, similar to mouse MCps in terms of amount and developmental state, has recently been identified in human blood. These have been reported to be lineage-negative $CD34^{hi}KIT^{int/hi}Fc\varepsilon RI^{+}$ cells and to give rise only to granulated tryptase-positive $KIT^{+}Fc\varepsilon RI^{+}$ MCs.[14] Interestingly, the frequency of development of such MCs starting from a lineage-negative $CD34^{hi}KIT^{int/hi}Fc\varepsilon RI^{-}$ cell subset was reduced by more than a factor of 10, indicating the importance of FcεRI expression for MC commitment.

After leaving the BM, MCps are distributed through the blood to their target tissues. This requires productive interaction between surface molecules of MCps and endothelial cells for transendothelial migration. Homing of MCps to the small intestine requires expression of the α4β7 integrin on MCps[15] and mucosal vascular addressin cell adhesion molecule 1 and vascular cell adhesion molecule 1 as counterligands on intestinal endothelial cells for interaction.[15,16] Integrin activation requires chemokine receptor–mediated inside-out signaling by CXCR2 expressed on MCps.[16] Although β7 integrin–deficient mice showed impaired MCp homing to the intestine, homing to the lung was still possible, although reduced. By using a model of ovalbumin-induced allergic airway inflammation, pulmonary recruitment of MCps was shown to depend on both α4β7 and α4β1 integrins on the MCps and on vascular cell adhesion molecule 1 on the endothelial side.[17] The same transmigration mechanism was recently demonstrated in influenza A–infected mice.[18]

Homing of MCps to the small intestine occurs in a constitutive manner in naive mice,[15] although it can be amplified by inflammatory conditions. In contrast, in the lung the numbers of MCps that home constitutively is strongly exceeded by numbers recruited on inflammation in a T cell–dependent manner.[19] In addition to the intestine and the lung, the skin is an important

MC-containing tissue. However, less is known about MCps homing to the skin, although a promoting role for the fractalkine receptor CX3CR1 on MCps has been suggested.[20]

After migration to their respective tissues, MCps differentiate into 2 major subclasses of mature tissue MCs: MC_{TC}s and MC_{T}s (see the section "Heterogeneity of mast cells"). Finally, maturation of MCs, both *in vitro* and in different tissues, is associated with downregulation of cell-surface adhesion molecules and chemokine receptors. As an example, primary peritoneal and pulmonary MCps from naive mice express considerably higher levels of β7 integrin than the respective mature MCs.[21] Moreover, analysis of MCps and mature MCs differentiated *in vitro* from human cord blood revealed expression of 4 different chemokine receptors (CXCR2, CCR3, CXCR4, and CCR5) on MCps, whereas only CCR3 was retained on mature MCs.[22] Generally, expression of plasma membrane proteins important for migration changes during MC maturation.

Very recently, with the aid of a new hematopoietic fate mapping model, murine MCs were demonstrated to have dual developmental origins arising through both primitive (yolk sac–derived) and definitive (HSC-derived) hematopoiesis.[23] MC maintenance in adult tissues was found to occur largely independent of the BM, probably through proliferation of tissue-resident MCps differentiated from HSCs during embryogenesis.[23] This intriguing study proves that much more remains to be discovered in MC development and migration to target tissues, and it would be exciting to learn about the respective processes in human subjects.

REGULATION AND FUNCTION OF MC PROTEASES

Proteases, particularly tryptases, chymases, and CPA3, expression of which is largely restricted to MCs, contribute importantly to the pleiotropic effector functions of these cells. Proteases are the major proteins of MC secretory granules, which also contain histamine, serotonin, and proteoglycans. After release by means of degranulation, these proteases primarily exert proinflammatory functions and have been implicated in the pathogenesis of MC-related disorders, but they also contribute to tissue homeostasis and host defense.[24-26]

Human MCs express 4 tryptases (α, β, γ, and δ), 2 proteases with chymotrypsin-like activity (chymase and cathepsin G [also expressed in neutrophils]), and CPA3. Tryptase β, which forms noncovalent tetramers with limited trypsin-like activity, is considered the prototypical and biological active "tryptase."[27,28] Tryptase α can assemble to virtually identical tetramers but is inactive.[29] Tryptase δ lacks the C-terminal 40-amino-acid residues,[30] and from a structural point of view, its folding and activity are enigmatic. Tryptase γ is less closely related to the other tryptases, and it is likely membrane bound in a monomeric form.[31] Although chymase and CPA3 are exclusive to MCs, chymase, cathepsin G, and CPA3 are usually expressed only in the MC_{TC} subset of MCs. MCs with distinct protease expression patterns, such as chymase-only MCs[32] and, more recently, $CPA3^{+}$ MC_{T}s have been described in patients with eosinophilic allergic inflammatory disorders.[33,34]

Comparative genomic analysis has shown that tryptases and chymases are poorly conserved between human subjects and rodents and even between human subjects and chimpanzees.[35] The mouse genome encodes 4 tryptases: mouse mast cell protease (mMCP) 6, mMCP-7, mMCP-11, and tryptase γ/transmembrane tryptase. mMCP-6 is most likely the functional counterpart of human tryptase β, whereas mMCP-7 apparently is dispensable and not expressed in some mouse strains, such as C57BL/6.[36] The chymase locus has expanded considerably and encodes 7 chymases: mMCP-1, mMCP-2, mMCP-4, mMCP-5, mMCP-8, mMCP-9, and mMCP-10. mMCP-4 appears to be the functional counterpart of human chymase, whereas its rodent orthologs mMCP-5 and rMCP-5 have altered elastase-like activity.[37,38] Instead of being expressed in MCs, mMCP-11 and mMCP-8 are preferentially expressed in basophils,[39,40] which are virtually devoid of tryptases and chymases in human subjects. In contrast to the heterogeneity of tryptases and chymases, a single CPA3 gene is expressed in human subjects and rodents.

Considering their role in host defense versus their proinflammatory potential, it is not surprising that the expression and activity of MC proteases is extensively regulated. On the genomic level, the variation of α- and β-tryptases is complex: of the 4 tryptase genes (*TPSAB1*, *TPSB2*, *TPSG1*, and *TPSD1*), *TPSAB1* and *TPSB2* can harbor alleles encoding enzymatically active β, inactive α, or deficiency alleles.[41] All subjects initially surveyed have 2 to 4 β alleles, suggesting that the β allele has essential functions, whereas the enzymatically inactive α allele is dispensable.[41] Recently, subjects with duplications or triplications of the α-encoding *TPSAB1* gene, increased basal serum tryptase levels, and multisystem complaints have been identified, a trait now classified as hereditary α-tryptasemia syndrome.[42] On the level of gene regulation, expression of human tryptase, its mouse counterpart mMCP-6, and several mouse chymases is driven by the microphthalmia-associated transcription factor, which is also central to the development of MCs.[43,44] Posttranscriptional and posttranslational mechanisms contribute to this regulation and result in an increased number of tryptase species. For example, alternative splicing of human α- and β-tryptases has been reported, which likely affects the tetrameric architecture, stability, and enzymatic activity of these proteins.[45] Posttranslational processing further results in several forms of the proteins with slight differences in glycosylation, charge, and enzymatic activity.[46] In contrast to most other proteases, tryptases and chymases are not regulated at the level of zymogen activation. Rather, they are activated by cathepsin C and potentially by other cathepsins before storage in granules, a feature shared with other "granule-associated serine proteases of immune defense."[47,48] Within the granules, the activity of tryptases and chymases is likely controlled by compartmentalization, its acidic pH, and its close packaging. After degranulation, binding to high-molecular-weight proteoglycans continues to modulate diffusion, activity, and substrate specificity. In particular, the active β-tryptase tetramer requires stabilization by bound proteoglycans that protect it from dissociation into (almost) inactive monomers. Enzymatically active monomers with altered substrates and inhibition profiles can be formed *in vitro*,[49] but these remain to be demonstrated *in vivo*. Tetramerization is likely the main mechanism regulating tryptase β activity and selectivity *in vivo* because it restricts the access of large substrates to the active sites located within the central pore and sterically blocks inhibition by most protease inhibitors.[26,28,50] Monomeric chymases are more prone to inhibition by tissue- and plasma-derived inhibitors, but they can evade inhibition by inactivating serpins and they can retain some activity when in circulation in an α_2-macroglobulin complex.[51]

MC RECEPTORS AND SIGNALING

Immunoglobulin receptor signaling and function

MCs express FcεRI and several IgG receptors (FcγRs) on their surfaces.[52,53] FcεRI is a tetramer consisting of an α-chain that binds IgE, a membrane transversing tetraspanin β-chain, and a homodimeric disulfide-linked γ-chain.[54,55] IgE is bound at 1:1 stoichiometry at very high affinity ($K_a \geq 10^{10}$ M^{-1}). Binding of low doses of monomeric IgE to FcεRI provides an MC survival signal,[56] and IgE levels affect surface expression of FcεRI.[57,58] Low binding of IgE or antigen to FcεRI triggers expression and secretion of chemokines and other mediators, whereas optimal binding triggers degranulation.[59] Supraoptimal cross-linking can suppress MC activation.[60] Human MCs express FcγRIIA, FcγRI, or both. Both receptors can stimulate degranulation and cytokine gene expression. In mice FcγRIIB, which is expressed also on human MCs, acts as an inhibitor, and FcγRIII is stimulatory on degranulation.

After cross-linking by antigen, IgE-prebound FcεRI is phosphorylated by the kinase LYN at tyrosine residues in the immunoreceptor tyrosine-based activation motifs of the β- and γ-chains. This is followed by activation of SYK and other kinases. The core signaling pathways have been extensively reviewed elsewhere.[53,55,61] The relationships among the 2 classes of enzymes, other kinases and phosphatases that control MC function, are complex and sometimes hierarchical. Much has been learned from "knockout" or "knockdown" models, which need to be interpreted with caution because compensatory mechanisms might be turned on. The balance of specific signaling pathways emanating from FcεRI depends on the MC type, its site of residence, its FcεRI-independent activation status, and other biological parameters.

Cross-linking of FcεRI by IgE/antigen complexes causes it to translocate into lipid rafts.[62,63] LYN is tethered to the cytoplasmic membrane through acylation and coassembles in lipid rafts, which promote high local concentration of receptor and kinase, resulting in efficient phosphorylation of FcεRI. Other components of the FcεRI signalosome are embedded in these membrane domains as well, such as the transmembrane adapter proteins, LAT and NTAL. Not only are some proteins included in lipid rafts when FcεRI becomes cross-linked, but also others, such as certain phosphatases, are excluded from lipid rafts.[64] Thus formation of these lipid-protein domains provides a versatile mechanism for the regulation of FcεRI signaling. Other signals that modulate FcεRI-mediated degranulation likely include cell-cell contact-dependent signals from adhesion receptors (RJ; own unpublished results). Embedding MCs in appropriate tissue niches and thereby controlling MC activation might be an important mechanism to keep degranulation under finely balanced control. Many other factors that regulate the final outcome of FcεRI signals are incompletely understood, such as noncoding RNAs, membrane biophysics, intracellular liquid-phase separation, and physical interactions with other cells, including immune and nonimmune cells.

A large range of compounds from plant molecules to bacterial substances and snake venoms but also complement, Toll-like receptor (TLR) ligands, and other stimuli, such as pressure or heat, can cause MC exocytosis.[65] Thus a plethora of receptors can trigger MC degranulation independently of or in conjunction with FcεRI. MC FcεRI-mediated degranulation can also be facilitated by other pathways. Examples, such as SCF (see the section "Cytokine receptor signaling and function"), prostaglandins, nucleotides, interleukins, and chemokines illustrate the wide spectrum of ligands that modulate MC activity.[66]

MCs, at least BMMCs, can be desensitized by various pathways to keep FcεRI signaling and thus degranulation under control.[67,68] Low-dosage exposure to monomeric IgE, IgE-bound antigen, or anti-Fc receptor antibodies reduces FcεRI sensitivity.[69,70] Activation of the single-chain FcγRIIB by cross-linking it to FcεRI through immune complexes made of the immunoglobulin Fc fragments Fcγ and Fcε blocks phosphoinositide 3-kinase–mediated FcεRI signaling.[71] FcεRI can be downregulated by means of internalization, followed by either degradation or recycling to the cell surface.[61,72,73] Ubiquitination and neddylation are key signals for these endocytic processes and/or the potential subsequent lysosome- or proteasome-mediated degradation of the Fc receptor complexes.[63] Furthermore, signaling through cross-linked FcγRs can induce BMMC apoptosis.[74]

Cytokine receptor signaling and function

SCF, IL-4, and IL-33 are major cytokines regulating MC mediator release. SCF acts not only as an MC growth, survival, and chemotaxis factor but also as a regulator of mediator release by either enhancing IgE-dependent responses (both degranulation and production of leukotrienes and cytokines) or directly inducing cytokine production and release.[75,76] Mechanisms of activation of the SCF receptor KIT in MCs are quite well understood and have been reviewed elsewhere.[77,78] In contrast to the acute effects of SCF stimulation, chronic SCF treatment results in suppression of FcεRI-mediated MC activation caused by significant attenuation of cytoskeletal reorganizations.[79]

In a comparable manner acute IL-33 stimulation of MCs augments antigen-triggered cytokine production, as studied in BMMCs and human umbilical cord blood–derived MCs.[80,81] Interestingly, KIT has been shown to interact constitutively with the β-chain of the IL-33 receptor IL-1 receptor accessory protein, and it appears to be required for the full IL-33 response in BMMCs and human mastocytosis MC lines.[82] In opposition to acute stimulation with IL-33, chronic treatment of BMMCs and primary human MCs with IL-33 (>72 hours) resulted in a hyporesponsive secretory phenotype, demonstrating fundamental proteomic and regulatory changes induced by long-term IL-33 stimulation.[83]

In addition to SCF and IL-33, IL-4 is another important human MC regulator. In contrast to SCF, IL-4 does not affect matured MCs by itself but acts synergistically with SCF on MC survival, proliferation, and IgE-dependent mediator release.[3] Moreover, IL-4 alters the cytokine profile released by human intestinal and skin MCs (Fig 1).[84-86] Cytokines produced by MCs, either constitutively or on activation, vary in different species depending on the maturity of the MCs, tissue environmental factors, MC subtypes, and types of stimuli that trigger MC signaling. Below is a summary of data from primary human MCs, either MMCs from the gut[84,85] or skin.[86,87]

MMCs from the gut express constitutively small amounts of TNF-α and IL-6. On FcεRI cross-linking, expression of TNF-α and IL-6 is enhanced, and additional expression of T_H2 cytokines, such as IL-3, IL-5, and IL-13, occurs. If the MMCs are exposed to an IL-4 environment, IL-6 expression is blocked, although IL-3, IL-5, and IL-13 expression is markedly enhanced. Similar



FIG 1. Expression of cytokines (**A** and **C**) and chemokines **(B)** in human MCs. Intestinal MCs were isolated from gut (Fig 1, *A* and *B*) and skin MCs from the foreskin and breast skin (Fig 1, *C*). Cytokine/chemokine mRNA expression without stimulation *(upper left quarter)*, after stimulation with IgE receptor cross-linking (*IgErcl*, *right quarters*), and after priming with IL-4 *(lower quarters)* are shown. Cytokine/chemokine mRNA expressions in boldface letters in the *upper right quadrants* were enhanced by IgE receptor cross-linking, whereas cytokine/chemokine mRNA expressions in boldface letters in the *lower right quadrants* were enhanced by IL-4.[84-86]

variations in cytokine expression can be observed in human skin MCs depending on FcεRI cross-linking and IL-4 treatment. However, no T_H2 cytokine expression has been described in this cell type (Fig 1, *C*). Human MMCs are also a rich source of several chemokines, expression of which is again regulated by FcεRI cross-linking and IL-4 (Fig 1, *B*).

Human skin MCs produce chemokines also, namely CCL2, CCL3, and CCL4, on activation by CD30, but their regulation has been less extensively studied.[87] The priming effect of IL-4 is likely not restricted to intestinal or skin MCs but has been observed also in lung MCs, the human MC line LAD2, and other human MCs.[88-91]

IL-4 is a key mediator of allergic inflammation, considering that it also induces development of T_H2 cells and IgE switching in B cells.[3] Thus SCF and IL-4 can be considered primary costimulatory mediators because they not only enhance FcεRI-mediated signals but also induce upregulation of secondary stimulatory receptors, such as the substance P (NK-1) receptor. Such costimulation draws comparisons between MC and T-cell signaling because both require cooperation of 2 signals for optimal activation: an antigen-dependent signal, such as from the T-cell receptor or IgE-bound FcεRI, and a costimulatory molecule, such as CD80, in T cells or SCF/IL-4 in MCs.

The priming effect of IL-4 in human MCs is possibly not restricted to FcεRI-mediated stimulation. In human cord blood–derived MCs, IL-4 pretreatment enhances TNF production after stimulation with the TLR2 agonist peptidoglycan and enables MCs to produce TNF in response to LPS.[92] In the LAD2 human MC line, IL-4 pretreatment enhances IL-31 production after stimulation with IL-33.[91] These 2 studies are probably insufficient for generalization of IL-4–priming effects in IgE-independent signaling in human MCs but demonstrate that the priming effects are not restricted to FcεRI-mediated stimulation.

The intracellular mechanisms connecting SCF and the IL-4 signaling pathway have been analyzed in human MC_Ts isolated from gut mucosa.[93] Activation of MC_Ts by means of FcεRI cross-linking alone results in phosphorylation of extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase (MAPK) p38 but not AKT. Stimulation with SCF alone also induces phosphorylation of ERK and MAPK p38 and additionally of AKT. As opposed to human MC_Ts, in murine BMMCs both KIT- and FcεRI-mediated stimulation results in ERK, MAPK p38, and AKT activation.[76] IL-4 priming of human intestinal MC_Ts enhanced activation of ERK but blocked activation of MAPK p38. Because activation of MAPK p38 is required for IL-6 production, the reported negative effect of IL-4 on MAPK p38 explains the inhibitory effect of IL-4 on IL-6 expression in human MCs. Moreover, IL-4 priming that antecedes FcεRI cross-linking induces activation of AKT. Combined treatment of MCs with IL-4, SCF, and FcεRI cross-linking substantially upregulates activation of AKT, whereas blocking of AKT inhibited the pronounced production and release of cytokines and chemokines in response to the 3 MC agonists.[93]

Innate immune receptors

The particular localization of MCs makes their expression of receptors recognizing microbial constituents meaningful and mandatory. MCs are equipped with different TLRs, which can productively interact with various pathogen-associated molecular patterns present on bacteria, viruses, and fungi. Differential types of MCs of different species have been reported to express various TLRs (investigated mainly at the mRNA level). TLR1 to TLR9 have been found in murine and human MCs,[94-96] whereas TLR10 can only be detected in human lung MCs.[97] By far most studies in the field of TLR function and signaling have been published for TLR4 and its ligand LPS. In macrophages LPS is bound by mCD14 and eventually transferred to the TLR4–MD-2 complex, hence activating the myeloid differentiation response gene–88 (MyD88)-dependent and TIR domain–containing adapter-inducing IFN-β (TRIF)–dependent pathway. The former induces production of proinflammatory cytokines, and the latter induces generation of type I interferons.[98] Intriguingly, BMMCs and human intestinal MCs lack mCD14, with the consequence that they recognize R-chemotypes of LPS but not S-chemotypes.[99,100] In correlation, macrophages deficient in CD14 show an LPS recognition phenotype comparable with MCs.[101]

Moreover, both murine BMMCs and murine peritoneal mast cells (PMCs) were found to lack the adaptor protein TRIF-related adapter molecule, resulting in their inability to activate the TRIF pathway and hence to produce type I interferons on LPS stimulation.[102,103] With respect to MyD88-dependent proinflammatory TLR4 signaling, B-cell lymphoma 3, a member of the inhibitor of nuclear factor κB family, has been shown to play a suppressive role in PMCs, which was not obvious in BMMCs.[104] Most likely, many more differences between diverse MC types are to be found at the level of signal transduction as well.

C-type lectin receptors have also been found to be involved in MC signaling activated by certain bacteria. MCs differentiated from murine BM or peritoneal cells express mannose receptor and macrophage galactose-type lectin, for which roles in the recognition of *Bordetella pertussis* have been demonstrated.[105] In addition, expression of the C-type lectin receptor Dectin-1, which participates in antifungal immunity, has been reported in different types of MCs, such as BMMCs,[106] human MCs generated from peripheral blood $CD34^+$ progenitors,[107] and cord blood–derived MCs.[108] Thus MCs are well endowed with different features for pathogen recognition.

Regulation of Ca^{2+}-dependent MC activation

MC activation by numerous stimuli relies on Ca^{2+} entry. Numerous stimuli, including antigen acting on IgE-bound FcεRI, adenosine, endothelin-1, or compound 48/80, for which the receptor in MCs (ie, MRGPRB2 in mice and MRGPRX2 in human subjects) was identified only 3 years ago,[109] trigger a marked increase in free cytosolic Ca^{2+} concentration to evoke MC activation. Degranulation achieved by means of regulated exocytosis of secretory vesicles requires an increase in free cytoplasmic Ca^{2+} concentration similar to the production of leukotrienes or activation of several transcription factors, which drive cytokine synthesis. Before degranulation can occur, vesicles loaded with, for example, inflammatory mediators are transported to the plasma membrane, where they fuse with the plasma membrane. This process of regulated exocytosis is initiated by an increase in the Ca^{2+} concentration in the vicinity of the membrane, which depends on Ca^{2+} influx through Ca^{2+}-permeable channels in the plasma membrane.[110,111]

A major downstream target of FcεRI stimulation is phospholipase C (PLC) γ1, which leads to generation of inositol-1,4,5-trisphosphate (IP_3). IP_3-mediated Ca^{2+} release from intracellular stores is subsequently followed by an influx of Ca^{2+} from the extracellular space, a process called store-operated Ca^{2+} entry (SOCE).[112] SOCE has been described in MCs,[111,113] and ionic currents mediating this Ca^{2+} influx were first characterized as Ca^{2+} release–activated Ca^{2+} (CRAC) channels.[114] Molecular constitutions of this Ca^{2+} entry pathway include proteins of the ORAI family. Depletion of intracellular Ca^{2+} stores through IP_3 generation can be achieved by several agonists mentioned above that act on G protein–coupled receptors (GPCR), leading to stimulation of PLCβ. These signaling pathways are also shown to activate transient receptor potential (TRP) channels.

Ca^{2+} entry into MCs through channels consisting of ORAI proteins. The ORAI family of cation channels consists of 3 members, ORAI1, ORAI2, and ORAI3, all of which are sufficient to build SOCE channels (see references in Tsvilovskyy et al[115] and (Table I).[115-128] In murine BMMCs in which the *Orai1* gene has been targeted by a gene-trap approach,[116] CRAC currents (I_{CRAC}) were reduced by 66%, and FcεRI-mediated Ca^{2+} entry and release of inflammatory mediators were reduced to a similar extent. In contrast, in *Orai2*$^{-/-}$ mice, antigen-evoked Ca^{2+} levels increase, and degranulation of PMCs and passive systemic anaphylaxis were increased.[115] This finding was initially surprising because overexpression of *Orai2* or *Orai1* cDNA leads to a pronounced enhancement of both SOCE and I_{CRAC} (see references in Tsvilovskyy et al[115]). An increase in SOCE was also observed in *Orai2*$^{-/-}$ T cells and macrophages,[129] which was explained by a role of ORAI2 proteins in fine-tuning the magnitude of SOCE mediated in ORAI1:ORAI2 heteromeric channels.[129] A Ca^{2+} increase triggered by compound 48/80 is increased in *Orai2*$^{-/-}$ PMCs, suggesting that Ca^{2+} entry channels triggered by MRGPRB2 receptors contain ORAI2 proteins.[115]

In human lung MCs, all 3 *ORAI* genes (also termed *CRACM* in some studies) are expressed. Adenovirus-mediated knockdown of *ORAI1* in human lung MCs resulted in a significant reduction of approximately 50% in Ca^{2+} influx and in FcεRI-dependent release of β-hexosaminidase and leukotriene C_4, whereas *ORAI2* knockdown had only marginal effects.[117] However, it is still unknown whether any of the 3 ORAI proteins contribute to Ca^{2+} entry and MC activation triggered by other agonists, such as those acting through GPCRs.

TRP channels determine Ca^{2+} entry into MCs. Twenty-eight mammalian TRP proteins are classified into 6 subfamilies according to structural homology: TRPC, TRPV, TRPM, TRPA, TRPML, and TRPP (see references in Freichel et al,[110] Table I). TRP channels not only contribute to Ca^{2+} entry across the plasma membrane but also play an important role in electrogenesis, regulating the driving force for Ca^{2+} entry through other Ca^{2+}-permeable channels, such as CRAC or other store-operated channels. In BMMCs indirect regulation, as a limiting factor of SOCE, was found to be a characteristic feature of TRPM4 channels, which act as Ca^{2+}-activated cation channels primarily conducting Na^+. TRPM4 channels depolarize the membrane after FcεRI stimulation, thereby critically decreasing Ca^{2+} influx through CRAC channels. Accordingly, TRPM4 deletion results in an increased Ca^{2+} entry and excessive release of

TABLE I. Summary of data concerning cation channel functional importance in primary MC models obtained by using knockout and knockdown approaches

Channel	Consequence of knockout or knockdown on: Ca^{2+} entry	Inflammatory mediator release	*In vivo* function in channel-deficient mice	References
Orai1	Decrease	Decrease	Regulation of passive cutaneous anaphylactic reaction	116,117
Orai2	Increase	Increase	Regulation of passive systemic anaphylaxis	115
TRPC1	Decrease; decreased frequency of Ca^{2+} wave initiation	Decrease	Regulation of recovery in passive systemic anaphylaxis	120-122
TRPC3	Decreased frequency of Ca^{2+} wave initiation	ND	ND	120
TRPC5	Decrease	Decrease	ND	123
TRPV1	No effect	No effect	ND	124
TRPV2	No effect on PMCs	Decrease	ND	124,125
TRPV4	No effect	No effect	ND	124
TRPM2	Decrease	Decrease	ND	126
TRPM4	Increase	Increase	Regulation of acute cutaneous anaphylaxis	118,119
TRPM7	ND	Decrease	ND	127
TRPM8	No effect	Decrease	Regulation of passive systemic anaphylaxis	128

ND, Not detected.

histamine, leukotrienes, and TNF-α and aggravates acute cutaneous anaphylaxis.[118] A similar role has recently been described in PMCs[119] in a study that demonstrated that TRPM4 proteins localize to the plasma membrane in response to FcεRI stimulation, suggesting that increased translocation of TRPM4 to the plasma membrane is part of the mechanism that limits MC activation.

The other TRP channels that contribute to MC activation do so by directly mediating Ca^{2+} entry. First evidence of the involvement of TRPC in MC activation came from knockdown experiments of TRPC1 and TRPC3 in RBL-2H3 cells, which resulted in decreased sensitivity to antigen stimulation.[120] Also, in BMMCs deficits in FcεRI-triggered MC activation were observed after TRPC1 downregulation.[121] However, contrary to expectations, analysis of *Trpc1*$^{-/-}$ mice showed a delayed recovery in passive systemic anaphylaxis, and *Trpc1*$^{-/-}$ BMMCs responded to antigen stimulation with an enhanced increase in intracellular Ca^{2+} compared with wild-type controls. Intriguingly, Ca^{2+} entry and degranulation triggered by antigen stimulation were unchanged.[122] Concerning the TRPC5 channel, Ma et al[123] found that TRPC5 downregulation in RBL-2H3 cells reduced SOCE and proposed an association of TRPC5 with STIM1 and ORAI1.

Within the TRPV subfamily, several studies have described expression of TRPV1, TRPV2, and TRPV4 in different types of mouse, rat, and human MCs,[110] including mouse PMCs.[124] However, the Ca^{2+} increase triggered by either antigen, endothelin-1, or compound 48/80 was unchanged in PMCs from TRPV1-, TRPV2- and TRPV4-deficient mice, respectively. In a similar manner degranulation triggered by antigen or compound 48/80 was unchanged.[124] Although degranulation induced by physical stimuli was found to involve TRPV2 activation in HMC-1 MCs,[125] the heat-evoked Ca^{2+} increase and degranulation were unchanged in *TRPV2*$^{-/-}$ PMCs.[124]

Within the TRPM subfamily, expression of TRPM2, TRPM4, TPRM7, and TRPM8 has been reported in different types of mouse, rat, and human MCs.[110] In *Trpm2*$^{-/-}$ BMMCs a heat-evoked cation current was lacking, and the antigen-evoked Ca^{2+} increase and degranulation were reduced.[126] Interestingly, SOCE levels were also reduced in *Trpm2*$^{-/-}$ BMMCs, and the authors raised the concept that TRPM2 can act as a store-operated channel independently of ORAI1. TRPM7, like TRPM6, serves as a bifunctional protein, with the protein kinase domain fused to an ion channel. TRPM7 is permeable to divalent cations including Mg^{2+} and Ca^{2+}. TRPM7 currents and histamine release evoked by either macrophage inflammatory protein 1α or substance P are significantly reduced in PMCs from mice lacking the TRPM7 kinase domain.[127] TRPM8 can be activated by cold and cooling compounds, such as menthol. *Trpm8*$^{-/-}$ mice showed enhanced passive systemic anaphylaxis, which could not be explained by alterations in the antigen-evoked Ca^{2+} increase or degranulation measured in BMMCs, suggesting that TRPM8 expressed on non-MCs can contribute to the protective role of TRPM8 during anaphylaxis.[128]

Taken together, it is commonly accepted now that the intracellular [Ca^{2+}] increase is indispensable for MC activation, and numerous studies demonstrate that proteins of the ORAI and TRP families are essential constituents or modulators of antigen-induced Ca^{2+} entry; however, the Ca^{2+} entry pathways evoked by stimulation of GPCRs in MCs remain unclear and will be the subject of upcoming studies.

Phosphatase regulators of MC signaling

MC effector functions are controlled by regulatory systems that act to counterregulate excessive activation that would otherwise lead to disease. One of these regulatory systems is represented by phosphatases that inhibit the action of the kinases whose activity is triggered by the activation of different MC receptors.

The role of phosphatases in different MC models has been reviewed in recent years. Although most of them have predominantly negative regulatory activities through removal of differential phosphorylation in the MC signaling cascade (eg, protein tyrosine phosphatase α[130] and ε,[131] SH2 domain–containing inositol-5′-phosphatase 1[132,133] and 2,[134] phosphatase and tensin homolog,[135] the phosphatidate phosphatase LIPIN-1,[136] and T-cell ubiquitin ligand 2[137]), others exert positive activities (eg, dual-specificity phosphatase [DUSP] 2[138]) and some even possess both regulatory properties (positive and negative; eg, CD45[139,140]

TABLE II. Phosphatase regulators of MC functions

Phosphatase	Function in BMMCs	Function in mice	References
Negative regulators			
PTPα	FcεRI-mediated degranulation	FcεRI-mediated anaphylaxis	130
PTPε	Degranulation and cytokine production	FcεRI-mediated passive systemic anaphylactic reaction	131
SHIP1	Degranulation and FcεRI-mediated IL-6, TNF, and IL-5 production	Allergic inflammation and MC hyperplasia	132,133
SHIP2	FcεRI-mediated degranulation and cytokine (IL-4 and IL-13) gene expression	—	134
PTEN	FcεRI-mediated degranulation and cytokine (IL-3 and IL-6) production and survival	Antigen and SCF-induced allergic response	135
LIPIN-1	FcεRI-mediated degranulation and prostaglandin D_2 release	FcεRI-mediated passive systemic anaphylaxis	136
TULA-2	FcεRI-mediated degranulation	—	137
Positive regulators			
DUSP2	FcεRI-mediated IL-6 and TNF expression	Promotes the "K/BxN" model of inflammatory arthritis that depends on MCs and macrophages	138
Dual positive and negative regulators			
CD45	Negative: degranulation and IL-3–dependent proliferation Positive: Degranulation and cytokine secretion	Positive: FcεRI-mediated systemic anaphylaxis	139,140
SHP-1	Negative: IL-4, IL-13, IL-6, and TNF expression on H_2O_2, LPS, and FcεRI cross-linking Positive: IL-3–dependent proliferation	Negative: allergic response	141-144
SHP-2	Negative: Ca^{2+} mobilization Positive: FcεRI-mediated TNF secretion	—	146

PTEN, Phosphatase and tensin homolog; *PTP*, protein tyrosine phosphatase; *SHIP*, SH2 domain–containing inositol-5′-phosphatase; *SHP*, SH2 domain–containing phosphotyrosine phosphatase; *TULA-2*, T-cell ubiquitin ligand 2.

and SH2 domain–containing phosphotyrosine phosphatase 1[141-144] and 2[145,146]). Almost all the studies on the role of phosphatases in MC function were performed on phosphatase-deficient mice or BMMCs, which are mucosal-like MCs (Table II).[130-144,146] Because reports have been made on subtle differences in phosphatase function in different types of tissue-resident MCs,[133] future studies will be needed to compare the role of phosphatases in different MC types.

A number of the phosphatases are transcriptionally regulated by glucocorticoids (GCs), which are famous therapeutically for their antiallergic and anti-inflammatory actions. GCs in general are known to exert their antiallergic actions on MCs by binding to an intracellular receptor (the GC receptor) that then interacts with a number of proinflammatory transcription factors, such as activator protein 1 or nuclear factor κB, to downregulate their activity.[147] However, GCs also acting through the GC receptor activate the expression of certain phosphatases as an indirect means of downregulating MC action.

DUSP1 (also known as MAPK phosphatase 1) was the first GC-inducible phosphatase gene reported to inhibit MC action through dephosphorylation of the MAPKs ERK1 and ERK2 in RBL-2H3 rat basophilic leukemia cells, which have been widely used as rat MMCs.[148,149] Later studies carried out in BMMCs showed a more complex regulatory effect of GCs. GC-induced activation of DUSP1 was found to be important for dephosphorylation of the MAPK p38 at early time points (4-8 hours), whereas it did not alter the phosphorylation of ERK1/2 or c-Jun N-terminal kinase. This shows a difference in the regulatory action of DUSP1 in BMMCs compared with RBL-2H3 cells that have been used repeatedly in many MC signaling studies. The results of the GC-induced DUSP1 expression also showed that only a subset of MAPKs was regulated by DUSP1 in BMMCs.[150] Therefore it was not surprising that GC-mediated inhibition of proinflammatory cytokine and chemokine gene expression (*Ccl2*, *Il6*, and *Tnf*), as well as degranulation, were unaltered in BMMCs from *Dusp1*$^{-/-}$ mice.[150]

A search for other mechanisms that might accompany GC regulation of MC function showed that several other phosphatases were transcriptionally upregulated by GCs in MCs. Intriguingly, in *Dusp1*$^{-/-}$ BMMCs GC upregulated the expression of phosphatases, such as DUSP2, DUSP4, DUSP9, and PEST domain-enriched tyrosine phosphatase (PEP).[150] Of these GC-regulated phosphatases, PEP is the most studied. Unlike the other GC-regulated phosphatases, PEP is exclusively expressed in hematopoietic cells.[151] In addition, disease-associated studies showed that alterations in *LYP*, the gene that codes for the human homolog of PEP, is a risk factor for human diseases, including inflammatory conditions, such as rheumatoid arthritis,[152] for which GC therapy is used.[153]

PEP is a potent negative regulator of T-cell receptor signaling that acts on receptor-coupled protein tyrosine kinases in T cells.[154,155] However, in BMMCs *Pep* gene deletion resulted in reduced antigen-mediated MC responses, such as serum histamine release, and a decreased number of degranulated MCs in the skin of knockout compared with wild-type mice, suggesting a positive regulatory function of this phosphatase.[156] GC-mediated inhibition of c-Jun N-terminal kinase 1/2 and PLCγ1 phosphorylation and Ca^{2+} mobilization after FcεRI cross-linking was abolished in *Pep*$^{-/-}$ BMMCs.[156] These studies show that although PEP expression is positively regulated by GCs, PEP is not a negative regulator of MC action, an apparent discrepancy in the putative role of this phosphatase in GC action.

Thus whole-genome expression profiling has recently been carried out using RNA sequencing analysis on $Pep^{+/+}$ and $Pep^{-/-}$ BMMCs to find a mechanistic explanation for the action of PEP in the regulation of MC activity and GC action (see GSE108972 for expression profiling data). These results identify PEP as a positive and negative regulator of MC functions. In its absence cytokine and chemokine gene expression (eg, *Tnf*, *Il13*, and *Csf2*) was downregulated, whereas expression of other genes (eg, *Il33*, *Ccr1*, *Il1r1*, and *Tnfrsf12a*) was upregulated in response to antigen (see GSE108972).[157] Furthermore, PEP was needed for the antiallergic action of GCs in MCs because GC-induced negative regulation of antigen-mediated *Cox2* gene expression was attenuated in $Pep^{-/-}$ BMMCs (GSE108972),[157] showing that PEP is a promising target in antiallergic therapy. In this light some attempts have already been made to inhibit PEP activity by using small-molecular-weight compounds. The first attempt was with an Au(I)-phosphine complex, but because this was less specific,[156] a more selective inhibitor, L75NO4, has since been described.[158] Further studies will be needed to determine whether PEP/LYP is a valid target for future therapeutic approaches for MCs in human subjects.

PHYSIOLOGIC FUNCTIONS OF MCs

Chemotaxis and phagocytosis

Generally, MCs are thought of as long-lived tissue-resident cells with little turnover. The traditional thought is that there is a continuous stream of MCps from the BM, circulating in the blood and replenishing peripheral sites in which final maturation happens. This view has very recently been challenged by using lineage-tracing experiments that show very little MC replenishment of peripheral tissues from the BM.[23] In many inflammatory settings, however, MC numbers strongly increase in target tissues. Local cell divisions alone, if mature and terminally differentiated MCs would proliferate at all, could not account for the massive increase in MC numbers.[17] Thus MC migration remains an important and insufficiently understood aspect of MC biology.[6,12,159-162]

MC chemotaxis is often assayed *in vitro* by using transwell assays or similar approaches and less often *in vivo* by using injection of labeled MCs through the tail vein and analysis of their arrival at certain anatomic locations, including the skin, peritoneal fluid, and small intestine. However, many of these experiments used mouse models carrying deficiencies in the KIT/KITL system that have multiple effects and thus are problematic. Depletion of specific MC populations, such as through MC-specific diphtheria toxin expression, followed by their reconstitution from BM transfer, has proved an important tool in many studies.[163-165] Yet, under nonchallenged conditions, reconstitution was slow and seemed to occur from endogenous MCps not affected by the toxin.[23]

The most prominent receptors described above, FcεRI and KIT, were also found to act on MC migration, and thus IgE and SCF are potent inducers of MC migration. Antigen-mediated migration (ie, IgE/antigen-triggered FcεRI activation that causes MCs to migrate) was observed, for example, after sensitizing mice and challenging their lung airways with aerosolized antigen. KIT-triggered pathways are involved not only in proinflammatory MC activation but also in migration. Key to migratory behavior and the required F-actin– and tubulin-dependent cytoskeletal dynamics[162] are RHO GTPases, particularly RAC, RHOA, and CDC42, and their regulatory factors.[166,167] Chemotaxis toward SCF expressed by endothelial cells and fibroblasts has been demonstrated numerous times *in vitro* for mouse and human cultured MCs.[168,169] Because some MCp populations express only low levels of KIT, in such cases SCF can support chemotaxis that is mainly triggered by chemokines, such as CCR2.[170]

The chemotactic landscape, even for the same tissue, is highly complex and depends on a plethora of parameters, including species, strain, age, activation status, cell type involved, and sex, and thus generalized predictions are very difficult, as is the assignment of direct effects of chemoattractant to a specific MC type. MC chemotaxis is also induced by many other agents as diverse as lipid mediators, such as sphingosine-1-phosphate (S1P), leukotriene B_4, and prostaglandins (prostaglandin E_2), and by CC or CXC chemokines.[171-173] The respective receptors are found on the surfaces of MCs, including 2 S1P receptors (S1P1 and S1P2) and chemokine receptors, such as CCR3, CCR5, CXCR2, and CXCR4. For example, in CXCR2-deficient mice MCs do not home efficiently to the intestines.[10,16,160]

Cytokine signaling can result in stimulatory or inhibitory effects on migration; for example, the anti-inflammatory IL-10 inhibits TNF-α– or nerve growth factor–induced MC migration.[174] Migration is affected by the environment through which MCs migrate, such as the extracellular matrix and/or other cell types. Indeed, some immune cells substantially support reconstitution of MC-depleted tissues. Dendritic cells, for example, but not lymphocytes, promote MCp trafficking to the intestine.[175]

When immature MCs reach a site of inflammation or mature resident MCs become locally activated near that site, these MCs (potentially further matured) not only rapidly degranulate and express further mediators but also can become actively involved in phagocytosis. MCs are strategically located in the skin, airways, gut, and other surface-exposed places to defend attacking microbes. In the skin MCs are estimated at a density of 3000 to 7000 cells per cubic millimeter and thus are prone to contact and attack invading pathogens.[176]

Studies using BMMCs indicate that to combat pathogens, the cells can phagocytose using complement and FcγRs, as well as CD48 and TLRs, and thus are involved in opsonin-dependent and independent means of defense, respectively.[177] Bacteria, such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecium*, are phagocytosed by using mouse BMMCs or human cord blood–derived MCs. The endosome-lysosome axis in MCs was reported to internalize and kill pathogens through either reactive oxygen species or nonoxidative means.[178] These conclusions are debatable because other authors did not find intracellular destruction of bacteria but rather extracellular attachments. Furthermore, some bacterial strains can enter MCs and thereby protect themselves from immune attack, although at least some of the bacteria, such as *Staphylococcus aureus*, will be destroyed intracellularly.[179,180]

The pathogenic fungus *Candida albicans* is found on mucosa and thus at a site prominently populated by MCs. The contribution of MCs to defense against *Candida albicans* is controversial because some authors suggest that MCs primarily fight the fungi through extracellular means,[181] whereas others describe phagocytotic killing of the fungus. After recognition through TLR2 and Dectin-1 receptors, *Candida albicans* was reported to be phagocytosed by BMMCs and killed by a nitric oxide–dependent mechanism.[182]

After phagocytosis, MCs display pathogenic peptides on their surfaces, thus supporting the adaptive immune response through this antigen-presenting activity. A further twist of the defense strategies used by MCs, although suicidal, is formation of extracellular traps.[183] Here MCs release DNA to trap microbes that stick to the viscous material. The MCs die, but this process is not accidental but rather a programmed mechanism that apparently involves high reactive oxygen species production.

Host defense against pathogens

MC_Ts are important immune cells that fight off selected species of intestinal nematodes (eg, *Trichinella spiralis* and *Strongyloides venezuelensis*), and worm expulsion is closely associated with intestinal mastocytosis. Different kinetics of resolution of infection correlate with the ability of different mouse strains to mount intestinal MC_T responses.[184] Immune elimination of primary nematode infection in rats correlated with secretion of the neutral protease rat MC protease II from MMCs.[185] Moreover, glycosaminoglycans, such as chondroitin sulfate A and heparin, stored in secretory lysosomes of MCs have been found to inhibit attachment and invasion of adult worms into the intestinal epithelium, hence promoting worm expulsion.[186]

About 20 years ago, a critical protective role of serosal-type MCs was described by using a murine model of acute septic peritonitis, cecum ligation, and puncture.[187,188] MC-secreted TNF-α on bacterial recognition acted as a chemotactic ligand for neutrophils necessary for the eradication of bacteria. These data were collected comparing WT and *Kit* mutant MC-deficient $Kit^{W/Wv}$ mice, which are known to exert additional hematopoietic abnormalities, such as neutrophilia and deficiency of peritoneal macrophages.[189,190] Piliponsky et al[190] advised caution in formulating general statements because they found the effect of MC deficiency to depend on mouse strain background, the nature of the mutation causing MC deficiency, and both the type and severity of infection.[190] In particular, MC engraftment of MC-deficient C57BL/6-$Kit^{W\text{-}Sh/W\text{-}Sh}$ mice even resulted in increased mortality during severe cecum ligation and puncture or on intraperitoneal inoculation of *Salmonella typhimurium*.[190] Moreover, when using a *Kit* mutant–independent mouse model, allowing conditional ablation of MCs, MCs were found to aggravate severe septic peritonitis by secreting IL-4, which in turn acted on peritoneal macrophages, attenuating their phagocytosis of bacteria.[165] Nevertheless, although the role of MCs in infection and immunity obviously is multifaceted, it is without a doubt that MCs are important actors in infectious and immunologic scenarios by secreting various mediators and/or regulating responses of myeloid and lymphoid immune cells.

Protection and regulation of tissue barriers

MCs are favorably located at boundaries where the host and environment meet, such as the skin or the mucosa of the lung and gastrointestinal tract. The intestinal mucosa is the largest boundary of the human body (estimated to be 200-400 m^2) and a most challenging one because the intestine hosts a large number of bacteria that need to be controlled to prevent host invasion. The second largest boundary is the respiratory mucosa (estimated at 100-200 m^2), whereas other mucosal sites (<1 m^2) and the skin (2 m^2) are rather small. Such boundaries are equipped not only with MCs but also with numerous cells of the innate and adaptive immune system, suggesting tight communication between these cells, as well as with tissue cells, including epithelial cells, endothelial cells, fibroblasts, and keratinocytes. The boundaries form unique functional barriers to protect the host against toxins, pathogens, and other harmful agents. MCs contribute to such barrier functions. In the intestine MCs regulate blood flow, smooth muscle contraction and peristalsis, mucosal secretion, and innate and adaptive immune responses.[191,192] This explains why MCs are involved in so many different types of gastrointestinal diseases, not only allergic disorders but also gastrointestinal infections and chronic inflammatory disorders, colon cancer, and other malignancies.[193]

The most effective stimulus for MMCs is cross-linking of cell surface–bound IgE, either by allergen in sensitized subjects or by parasitic antigens. However, this pathway is likely of no importance in healthy nonallergic subjects. It is not yet clear which stimuli might play a role in MC activation in healthy persons. Little is known about IgE-independent triggers of human MMCs of the lung or gastrointestinal tract. They might differ from triggers for human skin MCs or MCs from other species.[91,92] Important progress has been made in understanding MC regulation through the discovery of several inhibitory mechanisms that might balance the agonistic activities of mediators discussed previously.[194] Of particular relevance to the gastrointestinal tract are the anti-inflammatory cytokines TGF-β1 and IL-10, which are highly expressed in the healthy intestine. TGF-β1 inhibits SCF-dependent growth of human gastrointestinal MCs *in vitro* and modulates the mediator profile released on FcεRI aggregation by reducing proinflammatory mediator release, except for prostaglandin D_2 production, which is enhanced by TGF-β1.[195]

Multiple studies in rodents and, to some extent, also in human subjects have shown that MCs have a central role in host defense against bacteria, viruses, and parasites (see the "Host defense against pathogens" section). More recently, it was shown that gastrointestinal MCs interact also with commensal bacteria in the intestine. For example, intestinal commensal bacteria regulate the migration of murine MCs into the intestine through induction of CXCR2 ligands from intestinal epithelial cells in a TLR-dependent manner. Germ-free mice have lower MC densities in the small intestine than normal mice.[196] On the other hand, commensal bacteria, such as *Enterococcus faecalis*, suppress degranulation of MCs, at least *in vitro*, in a MyD88-independent manner, for example through partial inhibition of Ca^{2+} signaling on FcεRI cross-linking.[197]

It is tempting to speculate that MC–commensal bacteria interactions play a role in the gastrointestinal barrier and in protection against barrier-related diseases. By using *in vitro* models, it could be demonstrated that MC proteases are directly responsible for the increase in epithelial paracellular permeability.[198] The MC-dependent modulation of intestinal permeability was confirmed in human subjects exposed to stress.[199] The fact that gastrointestinal MCs are in intimate contact with the epithelium and nerves suggests further that MCs are involved in regulating mucosal permeability and intestinal barrier function.

Most of the physiologic functions of MCs described for the gut also apply to the lung. However, a comprehensive study of MC functions in normal lung physiology is lacking. Most work focuses on MC functions in the pathogenesis of asthma and other pulmonary diseases. It was only recently pointed out that MCs and their activation contribute to lung health through innate and adaptive immune responses to respiratory pathogens.

Human skin MCs are quite distinct in their development, functions, and biological properties compared with human MMCs. Skin MCs are sensitive to stimulation by substance P, compound 48/80, and other basic nonimmunologic stimuli. Moreover, skin MCs are also important players in protective immune responses against pathogens.

The fact that MCs are largely found at interfaces between the environment and the internal milieu predestines them to be involved in wound healing and tissue remodeling. Wound healing is a complex process of lysis and reconstitution controlled by a series of cell-signaling proteins. MCs have been shown to play a significant role in the early inflammatory stage of wound healing and also to influence proliferation and tissue remodeling in the skin.[200] In the skin, but also in the lung and intestinal mucosa, MCs are located around small vessels that are involved in vasodilation. MCs intimately communicate with endothelial cells providing MC growth factors, and in consequence of this communication, MCs are involved in regulation of extravasation of blood-derived immune cells.[201] In summary, MCs regulate a large number of physiologic tissue functions, namely maintenance of tissue barriers.

CONCLUSIONS

The mechanisms underlying pleiotropic MC functions to support the host's homeostasis have been unraveled to a large extent within the last few decades. MCs vary considerably depending on their grade of maturation, growth and trigger factors, tissue environmental conditions, and presence or absence of pathogens. MCs express a large variety of receptors, allowing them to respond specifically to particular conditions. Their major effector functions, the physiologic importance of which has to be elucidated in many cases, comprise the generation and release of proteases, amines, and cytokines, as well as chemotaxis and phagocytosis. These functions are regulated by SCF, IL-4, and other cytokines and chemokines; IgE and IgG receptor–dependent mechanisms; and innate immune receptors and other mechanisms and depend on an intracellular Ca^{2+} increase that is mediated or modulated by TRP and ORAI channels in many cases. Such mechanisms explain how MCs, both in human subjects and in different animal species, can exert a number of physiologic functions, including host defense against pathogens and regulation of mucosal and skin functions. The understanding of such mechanisms not only explains particular body functions but also offers novel opportunities for pharmacologic interventions.

We regret that we are unable to cite all relevant studies because of space limitations, and we apologize to our colleagues whose work has not been cited.

REFERENCES

1. Dvorak AM, Morgan ES. Diamine oxidase-gold enzyme-affinity ultrastructural demonstration that human gut mucosal mast cells secrete histamine by piecemeal degranulation in vivo. J Allergy Clin Immunol 1997;99:812-20.
2. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 1997;61:233-45.
3. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A 1999;96:8080-5.
4. Dwyer DF, Barrett NA, Austen KF. Immunological Genome Project Consortium. Expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nat Immunol 2016;17:878-87.
5. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol 2007;95:167-255.
6. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007;7:93-104.
7. Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS. Novel site-specific mast cell subpopulations in the human lung. Thorax 2009;64:297-305.
8. Fajt ML, Wenzel SE. Mast cells, their subtypes, and relation to asthma phenotypes. Ann Am Thorac Soc 2013;10(suppl):S158-64.
9. Frossi B, Mion F, Sibilano R, Danelli L, Pucillo CEM. Is it time for a new classification of mast cells? What do we know about mast cell heterogeneity? Immunol Rev 2018;282:35-46.
10. Hallgren J, Gurish MF. Pathways of murine mast cell development and trafficking: tracking the roots and routes of the mast cell. Immunol Rev 2007;217:8-18.
11. Xing W, Austen KF, Gurish MF, Jones TG. Protease phenotype of constitutive connective tissue and of induced mucosal mast cells in mice is regulated by the tissue. Proc Natl Acad Sci U S A 2011;108:14210-5.
12. Dahlin JS, Hallgren J. Mast cell progenitors: origin, development and migration to tissues. Mol Immunol 2015;63:9-17.
13. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. Science 1996;271:818-22.
14. Dahlin JS, Malinovschi A, Ohrvik H, Sandelin M, Janson C, Alving K, et al. Lin-CD34hi CD117int/hi FcεRI+ cells in human blood constitute a rare population of mast cell progenitors. Blood 2016;127:383-91.
15. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, Parker CM, et al. Intestinal mast cell progenitors require CD49db7 (a4b7 integrin) for tissue-specific homing. J Exp Med 2001;194:1243-52.
16. Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, Kuziel WA, et al. Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood 2005;105:4308-13.
17. Abonia JP, Hallgren J, Jones T, Shi T, Xu Y, Koni P, et al. a-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 2006;108:1588-94.
18. Zarnegar B, Mendez-Enriquez E, Westin A, Soderberg C, Dahlin JS, Gronvik KO, et al. Influenza infection in mice induces accumulation of lung mast cells through the recruitment and maturation of mast cell progenitors. Front Immunol 2017;8: 310.
19. Jones TG, Hallgren J, Humbles A, Burwell T, Finkelman FD, Alcaide P, et al. Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells. J Immunol 2009;183:5251-60.
20. Papadopoulos EJ, Fitzhugh DJ, Tkaczyk C, Gilfillan AM, Sassetti C, Metcalfe DD, et al. Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur J Immunol 2000;30:2355-61.
21. Dahlin JS, Ding Z, Hallgren J. Distinguishing mast cell progenitors from mature mast cells in mice. Stem Cells Dev 2015;24:1703-11.
22. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999;190:267-80.
23. Gentek R, Ghigo C, Hoeffel G, Bulle MJ, Msallam R, Gautier G, et al. Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells. Immunity 2018;48:1160-71.e5.
24. Caughey GH. Mast cell proteases as pharmacological targets. Eur J Pharmacol 2016;778:44-55.
25. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol 2014;14:478-94.
26. Sommerhoff CP, Schaschke N. Mast cell tryptase b as a target in allergic inflammation: an evolving story. Curr Pharm Des 2007;13:313-32.
27. Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, et al. Human b-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 1998;392:306-11.
28. Sommerhoff CP, Bode W, Pereira PJ, Stubbs MT, Sturzebecher J, Piechottka GP, et al. The structure of the human bII-tryptase tetramer: fo(u)r better or worse. Proc Natl Acad Sci U S A 1999;96:10984-91.
29. Marquardt U, Zettl F, Huber R, Bode W, Sommerhoff C. The crystal structure of human a1-tryptase reveals a blocked substrate-binding region. J Mol Biol 2002; 321:491-502.
30. Wang HW, McNeil HP, Husain A, Liu K, Tedla N, Thomas PS, et al. δ tryptase is expressed in multiple human tissues, and a recombinant form has proteolytic activity. J Immunol 2002;169:5145-52.
31. Wong GW, Foster PS, Yasuda S, Qi JC, Mahalingam S, Mellor EA, et al. Biochemical and functional characterization of human transmembrane tryptase (TMT)/

tryptase γ. TMT is an exocytosed mast cell protease that induces airway hyperresponsiveness in vivo via an interleukin-13/interleukin-4 receptor a/signal transducer and activator of transcription (STAT) 6-dependent pathway. J Biol Chem 2002;277:41906-15.

32. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract 1993;189:156-62.
33. Dougherty RH, Sidhu SS, Raman K, Solon M, Solberg OD, Caughey GH, et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol 2010;125:1046-53.e8.
34. Takabayashi T, Kato A, Peters AT, Suh LA, Carter R, Norton J, et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2012;130:410-20.e5.
35. Perez-Silva JG, Espanol Y, Velasco G, Quesada V. The Degradome database: expanding roles of mammalian proteases in life and disease. Nucleic Acids Res 2016;44:D351-5.
36. Hunt JE, Stevens RL, Austen KF, Zhang J, Xia Z, Ghildyal N. Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse. J Biol Chem 1996;271:2851-5.
37. Karlson U, Pejler G, Tomasini-Johansson B, Hellman L. Extended substrate specificity of rat mast cell protease 5, a rodent α-chymase with elastase-like primary specificity. J Biol Chem 2003;278:39625-31.
38. Kunori Y, Koizumi M, Masegi T, Kasai H, Kawabata H, Yamazaki Y, et al. Rodent α-chymases are elastase-like proteases. Eur J Biochem 2002;269:5921-30.
39. Ugajin T, Kojima T, Mukai K, Obata K, Kawano Y, Minegishi Y, et al. Basophils preferentially express mouse mast cell protease 11 among the mast cell tryptase family in contrast to mast cells. J Leukoc Biol 2009;86:1417-25.
40. Tsutsui H, Yamanishi Y, Ohtsuka H, Sato S, Yoshikawa S, Karasuyama H. The basophil-specific protease mMCP-8 provokes an inflammatory response in the skin with microvascular hyperpermeability and leukocyte infiltration. J Biol Chem 2017;292:1061-7.
41. Trivedi NN, Tamraz B, Chu C, Kwok PY, Caughey GH. Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol 2009;124:1099-105.e1-4.
42. Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016;48:1564-9.
43. Lee SH, Lee JH, Kim DK. Involvement of MITF-A, an alternative isoform of mi transcription factor, on the expression of tryptase gene in human mast cells. Exp Mol Med 2010;42:366-75.
44. Morii E, Tsujimura T, Jippo T, Hashimoto K, Takebayashi K, Tsujino K, et al. Regulation of mouse mast cell protease 6 gene expression by transcription factor encoded by the mi locus. Blood 1996;88:2488-94.
45. Jackson NE, Wang HW, Bryant KJ, McNeil HP, Husain A, Liu K, et al. Alternate mRNA splicing in multiple human tryptase genes is predicted to regulate tetramer formation. J Biol Chem 2008;283:34178-87.
46. Peng Q, McEuen AR, Benyon RC, Walls AF. The heterogeneity of mast cell tryptase from human lung and skin. Eur J Biochem 2003;270:270-83.
47. Caughey GH. A pulmonary perspective on GASPIDs: granule-associated serine peptidases of immune defense. Curr Respir Med Rev 2006;2:263-77.
48. Ahmad J, Bird PI, Kaiserman D. Analysis of the evolution of granule associated serine proteases of immune defence (GASPIDs) suggests a revised nomenclature. Biol Chem 2014;395:1253-62.
49. Hallgren J, Spillmann D, Pejler G. Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: formation of active tryptase monomers in the presence of low molecular weight heparin. J Biol Chem 2001;276:42774-81.
50. Sommerhoff CP, Sollner C, Mentele R, Piechottka GP, Auerswald EA, Fritz H. A Kazal-type inhibitor of human mast cell tryptase: isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis. Biol Chem Hoppe Seyler 1994;375:685-94.
51. Raymond WW, Su S, Makarova A, Wilson TM, Carter MC, Metcalfe DD, et al. a_2-macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity. J Immunol 2009;182:5770-7.
52. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol 2012;3:238.
53. Sibilano R, Frossi B, Pucillo CE. Mast cell activation: a complex interplay of positive and negative signaling pathways. Eur J Immunol 2014;44:2558-66.
54. Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989;337:187-9.
55. Suzuki R. The emerging picture of mast cell activation: the complex regulatory network of high-affinity receptor for immunoglobulin E signaling. Biol Pharm Bull 2017;40:1828-32.
56. Kashiwakura J, Otani IM, Kawakami T. Monomeric IgE and mast cell development, survival and function. Adv Exp Med Biol 2011;716:29-46.
57. Nomura I, Katsunuma T, Matsumoto K, Iida M, Tomita H, Tomikawa M, et al. Human mast cell progenitors in peripheral blood from atopic subjects with high IgE levels. Clin Exp Allergy 2001;31:1424-31.
58. Iida M, Matsumoto K, Tomita H, Nakajima T, Akasawa A, Ohtani NY, et al. Selective down-regulation of high-affinity IgE receptor (FcεRI) α-chain messenger RNA among transcriptome in cord blood-derived versus adult peripheral blood-derived cultured human mast cells. Blood 2001;97:1016-22.
59. Gonzalez-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-Dos-Santos A, et al. Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med 2003;197:1453-65.
60. Huber M. Activation/Inhibition of mast cells by supra-optimal antigen concentrations. Cell Commun Signal 2013;11:7.
61. Kuhny M, Zorn CN, Huber M. Regulation of FcεRI signaling by lipid phosphatases. Curr Top Microbiol Immunol 2014;382:111-27.
62. Draber P, Halova I, Levi-Schaffer F, Draberova L. Transmembrane adaptor proteins in the high-affinity IgE receptor signaling. Front Immunol 2011;2:95.
63. Varshney P, Yadav V, Saini N. Lipid rafts in immune signalling: current progress and future perspective. Immunology 2016;149:13-24.
64. Young RM, Zheng X, Holowka D, Baird B. Reconstitution of regulated phosphorylation of FcεRI by a lipid raft-excluded protein-tyrosine phosphatase. J Biol Chem 2005;280:1230-5.
65. Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell activation. Eur J Pharmacol 2016;778:33-43.
66. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006;6:218-30.
67. Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol 2002;14:698-704.
68. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006;117:1214-26.
69. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995;3:635-46.
70. Xiao W, Nishimoto H, Hong H, Kitaura J, Nunomura S, Maeda-Yamamoto M, et al. Positive and negative regulation of mast cell activation by Lyn via the FcεRI. J Immunol 2005;175:6885-92.
71. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fcγ Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat Med 2002;8:518-21.
72. Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R. Regulation of fc receptor endocytic trafficking by ubiquitination. Front Immunol 2014;5:449.
73. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 1996;383:263-6.
74. Fang Y, Larsson L, Bruhns P, Xiang Z. Apoptosis of mouse mast cells is reciprocally regulated by the IgG receptors FcγRIIB and FcγRIIIA. Allergy 2012;67:1233-40.
75. Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992;175:237-44.
76. Fehrenbach K, Lessmann E, Zorn CN, Kuhny M, Grochowy G, Krystal G, et al. Steel factor enhances supraoptimal antigen-induced IL-6 production from mast cells via activation of protein kinase C-β. J Immunol 2009;182:7897-905.
77. Galli SJ, Tsai M, Wershil BK, Tam SY, Costa JJ. Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol 1995;107:51-3.
78. Valent P, Ghannadan M, Hauswirth AW, Schernthaner GH, Sperr WR, Arock M. Signal transduction-associated and cell activation-linked antigens expressed in human mast cells. Int J Hematol 2002;75:357-62.
79. Ito T, Smrz D, Jung MY, Bandara G, Desai A, Smrzova S, et al. Stem cell factor programs the mast cell activation phenotype. J Immunol 2012;188:5428-37.
80. Andrade MV, Iwaki S, Ropert C, Gazzinelli RT, Cunha-Melo JR, Beaven MA. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol 2011;41:760-72.
81. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-8.

82. Drube S, Heink S, Walter S, Lohn T, Grusser M, Gerbaulet A, et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010; 115:3899-906.
83. Jung MY, Smrz D, Desai A, Bandara G, Ito T, Iwaki S, et al. IL-33 induces a hyporesponsive phenotype in human and mouse mast cells. J Immunol 2013;190: 531-8.
84. Feuser K, Thon KP, Bischoff SC, Lorentz A. Human intestinal mast cells are a potent source of multiple chemokines. Cytokine 2012;58:178-85.
85. Lorentz A, Schwengberg S, Sellge G, Manns MP, Bischoff SC. Human intestinal mast cells are capable of producing different cytokine profiles: role of IgE receptor cross-linking and IL-4. J Immunol 2000;164:43-8.
86. Babina M, Guhl S, Starke A, Kirchhof L, Zuberbier T, Henz BM. Comparative cytokine profile of human skin mast cells from two compartments—strong resemblance with monocytes at baseline but induction of IL-5 by IL-4 priming. J Leukoc Biol 2004;75:244-52.
87. Fischer M, Harvima IT, Carvalho RF, Moller C, Naukkarinen A, Enblad G, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006;116: 2748-56.
88. Hua X, Chason KD, Patel JY, Naselsky WC, Tilley SL. IL-4 amplifies the proinflammatory effect of adenosine in human mast cells by changing expression levels of adenosine receptors. PLoS One 2011;6:e24947.
89. Lin DA, Boyce JA. IL-4 regulates MEK expression required for lysophosphatidic acid-mediated chemokine generation by human mast cells. J Immunol 2005;175: 5430-8.
90. Okayama Y, Okumura S, Sagara H, Yuki K, Sasaki T, Watanabe N, et al. FcεRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur Respir J 2009;34:425-35.
91. Petra AI, Tsilioni I, Taracanova A, Katsarou-Katsari A, Theoharides TC. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. Allergy Asthma Proc 2018;39: 153-60.
92. Varadaradjalou S, Feger F, Thieblemont N, Hamouda NB, Pleau JM, Dy M, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003;33:899-906.
93. Feuser K, Feilhauer K, Staib L, Bischoff SC, Lorentz A. Akt cross-links IL-4 priming, stem cell factor signaling, and IgE-dependent activation in mature human mast cells. Mol Immunol 2011;48:546-52.
94. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004;173:531-41.
95. Saluja R, Delin I, Nilsson GP, Adner M. FcεRI-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment. PLoS One 2012;7:e43547.
96. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol 2001;167:2250-6.
97. Kulka M, Metcalfe DD. TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin. Mol Immunol 2006;43:1579-86.
98. Miyake K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 2004;12:186-92.
99. Brenner SA, Zacheja S, Schaffer M, Feilhauer K, Bischoff SC, Lorentz A. Soluble CD14 is essential for lipopolysaccharide-dependent activation of human intestinal mast cells from macroscopically normal as well as Crohn's disease tissue. Immunology 2014;143:174-83.
100. Huber M, Kalis C, Keck S, Jiang Z, Georgel P, Du X, et al. R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells. Eur J Immunol 2006;36: 701-11.
101. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, et al. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005;6:565-70.
102. Dietrich N, Rohde M, Geffers R, Kroger A, Hauser H, Weiss S, et al. Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria. Proc Natl Acad Sci U S A 2010;107:8748-53.
103. Keck S, Muller I, Fejer G, Savic I, Tchaptchet S, Nielsen PJ, et al. Absence of TRIF signaling in lipopolysaccharide-stimulated murine mast cells. J Immunol 2011;186:5478-88.
104. Poplutz M, Levikova M, Luscher-Firzlaff J, Lesina M, Algul H, Luscher B, et al. Endotoxin tolerance in mast cells, its consequences for IgE-mediated signalling, and the effects of BCL3 deficiency. Sci Rep 2017;7:4534.
105. Vukman KV, Ravida A, Aldridge AM, O'Neill SM. Mannose receptor and macrophage galactose-type lectin are involved in *Bordetella pertussis* mast cell interaction. J Leukoc Biol 2013;94:439-48.
106. Yang Z, Marshall JS. Zymosan treatment of mouse mast cells enhances dectin-1 expression and induces dectin-1-dependent reactive oxygen species (ROS) generation. Immunobiology 2009;214:321-30.
107. Ribbing C, Engblom C, Lappalainen J, Lindstedt K, Kovanen PT, Karlsson MA, et al. Mast cells generated from patients with atopic eczema have enhanced levels of granule mediators and an impaired Dectin-1 expression. Allergy 2011;66: 110-9.
108. Olynych TJ, Jakeman DL, Marshall JS. Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism. J Allergy Clin Immunol 2006;118:837-43.
109. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015;519:237-41.
110. Freichel M, Almering J, Tsvilovskyy V. The tole of TRP proteins in mast cells. Front Immunol 2012;3:150.
111. Ma HT, Beaven MA. Regulation of Ca2+ signaling with particular focus on mast cells. Crit Rev Immunol 2009;29:155-86.
112. Parekh AB, Putney JW Jr. Store-operated calcium channels. Physiol Rev 2005;85: 757-810.
113. Holowka D, Wilkes M, Stefan C, Baird B. Roles for Ca2+ mobilization and its regulation in mast cell functions: recent progress. Biochem Soc Trans 2016;44: 505-9.
114. Hoth M, Penner R. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 1992;355:353-6.
115. Tsvilovskyy V, Solís-López A, Schumacher D, Medert R, Roers A, Kriebs U, et al. Deletion of Orai2 augments endogenous CRAC currents and degranulation in mast cells leading to enhanced anaphylaxis. Cell Calcium 2018;71:24-33.
116. Vig M, DeHaven WI, Bird GS, Billingsley JM, Wang H, Rao PE, et al. Defective mast cell effector functions in mice lacking the CRACM1 pore subunit of store-operated calcium release-activated calcium channels. Nat Immunol 2008; 9:89-96.
117. Ashmole I, Duffy SM, Leyland ML, Bradding P. The contribution of Orai (CRACM)1 and Orai(CRACM)2 channels in store-operated Ca2+ entry and mediator release in human lung mast cells. PLoS One 2013;8:e74895.
118. Vennekens R, Olausson J, Meissner M, Bloch W, Mathar I, Philipp SE, et al. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat Immunol 2007;8:312-20.
119. Rixecker T, Mathar I, Medert R, Mannebach S, Pfeifer A, Lipp P, et al. TRPM4-mediated control of FcεRI-evoked Ca(2+) elevation comprises enhanced plasmalemmal trafficking of TRPM4 channels in connective tissue type mast cells. Sci Rep 2016;6:32981.
120. Cohen R, Torres A, Ma HT, Holowka D, Baird B. Ca2+ waves initiate antigen-stimulated Ca2+ responses in mast cells. J Immunol 2009;183:6478-88.
121. Suzuki R, Liu X, Olivera A, Aguiniga L, Yamashita Y, Blank U, et al. Loss of TRPC1-mediated Ca2+ influx contributes to impaired degranulation in Fyn-deficient mouse bone marrow-derived mast cells. J Leukoc Biol 2010;88:863-75.
122. Medic N, Desai A, Olivera A, Abramowitz J, Birnbaumer L, Beaven MA, et al. Knockout of the Trpc1 gene reveals that TRPC1 can promote recovery from anaphylaxis by negatively regulating mast cell TNF-α production. Cell Calcium 2013;53:315-26.
123. Ma HT, Peng Z, Hiragun T, Iwaki S, Gilfillan AM, Beaven MA. Canonical transient receptor potential 5 channel in conjunction with Orai1 and STIM1 allows Sr2+ entry, optimal influx of Ca2+, and degranulation in a rat mast cell line. J Immunol 2008;180:2233-9.
124. Solis-Lopez A, Kriebs U, Marx A, Mannebach S, Liedtke WB, Caterina MJ, et al. Analysis of TRPV channel activation by stimulation of FCeRI and MRGPR receptors in mouse peritoneal mast cells. PLoS One 2017;12:e0171366.
125. Zhang D, Spielmann A, Wang L, Ding G, Huang F, Gu Q, et al. Mast-cell degranulation induced by physical stimuli involves the activation of transient-receptor-potential channel TRPV2. Physiol Res 2012;61:113-24.
126. Oda S, Uchida K, Wang X, Lee J, Shimada Y, Tominaga M, et al. TRPM2 contributes to antigen-stimulated Ca(2)(+) influx in mucosal mast cells. Pflugers Arch 2013;465:1023-30.
127. Zierler S, Sumoza-Toledo A, Suzuki S, Duill FO, Ryazanova LV, Penner R, et al. TRPM7 kinase activity regulates murine mast cell degranulation. J Physiol 2016; 594:2957-70.
128. Medic N, Desai A, Komarow H, Burch LH, Bandara G, Beaven MA, et al. Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria. Cell Calcium 2011;50:473-80.
129. Vaeth M, Yang J, Yamashita M, Zee I, Eckstein M, Knosp C, et al. ORAI2 modulates store-operated calcium entry and T cell-mediated immunity. Nat Commun 2017;8:14714.

130. Samayawardhena LA, Pallen CJ. PTPa activates Lyn and Fyn and suppresses Hck to negatively regulate FcεRI-dependent mast cell activation and allergic responses. J Immunol 2010;185:5993-6002.
131. Akimoto M, Mishra K, Lim KT, Tani N, Hisanaga SI, Katagiri T, et al. Protein tyrosine phosphatase e is a negative regulator of FcεRI-mediated mast cell responses. Scand J Immunol 2009;69:401-11.
132. Haddon DJ, Antignano F, Hughes MR, Blanchet MR, Zbytnuik L, Krystal G, et al. SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo. J Immunol 2009;183:228-36.
133. Ruschmann J, Antignano F, Lam V, Snyder K, Kim C, Essak M, et al. The role of SHIP in the development and activation of mouse mucosal and connective tissue mast cells. J Immunol 2012;188:3839-50.
134. Leung WH, Bolland S. The inositol 5'-phosphatase SHIP-2 negatively regulates IgE-induced mast cell degranulation and cytokine production. J Immunol 2007; 179:95-102.
135. Furumoto Y, Charles N, Olivera A, Leung WH, Dillahunt S, Sargent JL, et al. PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. Blood 2011;118: 5466-75.
136. Shin J, Zhang P, Wang S, Wu J, Guan Z, Zhong XP. Negative control of mast cell degranulation and the anaphylactic response by the phosphatase lipin1. Eur J Immunol 2013;43:240-8.
137. de Castro RO, Zhang J, Groves JR, Barbu EA, Siraganian RP. Once phosphorylated, tyrosines in carboxyl terminus of protein-tyrosine kinase Syk interact with signaling proteins, including TULA-2, a negative regulator of mast cell degranulation. J Biol Chem 2012;287:8194-204.
138. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 2006;7:274-83.
139. Berger SA, Mak TW, Paige CJ. Leukocyte common antigen (CD45) is required for immunoglobulin E-mediated degranulation of mast cells. J Exp Med 1994; 180:471-6.
140. Grochowy G, Hermiston ML, Kuhny M, Weiss A, Huber M. Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems. Cell Signal 2009;21:1277-86.
141. Kamata T, Yamashita M, Kimura M, Murata K, Inami M, Shimizu C, et al. Src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest 2003;111:109-19.
142. Nakata K, Yoshimaru T, Suzuki Y, Inoue T, Ra C, Yakura H, et al. Positive and negative regulation of high affinity IgE receptor signaling by Src homology region 2 domain-containing phosphatase 1. J Immunol 2008;181:5414-24.
143. Zhang L, Oh SY, Wu X, Oh MH, Wu F, Schroeder JT, et al. SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung. J Immunol 2010;184:1180-90.
144. Nakata K, Suzuki Y, Inoue T, Ra C, Yakura H, Mizuno K. Deficiency of SHP1 leads to sustained and increased ERK activation in mast cells, thereby inhibiting IL-3-dependent proliferation and cell death. Mol Immunol 2011;48: 472-80.
145. Lu-Kuo JM, Joyal DM, Austen KF, Katz HR. gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. J Biol Chem 1999;274:5791-6.
146. McPherson VA, Sharma N, Everingham S, Smith J, Zhu HH, Feng GS, et al. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes FcεRI-induced activation of Fyn and Erk pathways leading to TNF a release from bone marrow-derived mast cells. J Immunol 2009;183:4940-7.
147. Oppong E, Flink N, Cato AC. Molecular mechanisms of glucocorticoid action in mast cells. Mol Cell Endocrinol 2013;380:119-26.
148. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
149. Seldin DC, Adelman S, Austen KF, Stevens RL, Hein A, Caulfield JP, et al. Homology of the rat basophilic leukemia cell and the rat mucosal mast cell. Proc Natl Acad Sci U S A 1985;82:3871-5.
150. Maier JV, Brema S, Tuckermann J, Herzer U, Klein M, Stassen M, et al. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 2007;21: 2663-71.
151. Matthews RJ, Bowne DB, Flores E, Thomas ML. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 1992;12:2396-405.
152. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T. Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 2008;26:29-55.
153. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
154. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 189:111-21.
155. Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 1999; 29:3845-54.
156. Obiri DD, Flink N, Maier JV, Neeb A, Maddalo D, Thiele W, et al. PEST-domain-enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice. Allergy 2012;67:175-82.
157. Ainooson GK, Gourain V, Stassen M, Cato AC. Transcriptomic data on the role of PEST-domain-enriched tyrosine phosphatase in the regulation of antigen-mediated activation and antiallergic action of glucocorticoids in mast cells. Data Brief 2018;20:1177-83.
158. He Y, Liu S, Menon A, Stanford S, Oppong E, Gunawan AM, et al. A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. J Med Chem 2013;56: 4990-5008.
159. Collington SJ, Williams TJ, Weller CL. Mechanisms underlying the localisation of mast cells in tissues. Trends Immunol 2011;32:478-85.
160. Hallgren J, Gurish MF. Mast cell progenitor trafficking and maturation. Adv Exp Med Biol 2011;716:14-28.
161. Halova I, Draberova L, Draber P. Mast cell chemotaxis—chemoattractants and signaling pathways. Front Immunol 2012;3:119.
162. Draber P, Sulimenko V, Draberova E. Cytoskeleton in mast cell signaling. Front Immunol 2012;3:130.
163. Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, et al. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity 2011;35:832-44.
164. Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Kohler A, et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 2011;34:973-84.
165. Dahdah A, Gautier G, Attout T, Fiore F, Lebourdais E, Msallam R, et al. Mast cells aggravate sepsis by inhibiting peritoneal macrophage phagocytosis. J Clin Invest 2014;124:4577-89.
166. Kuehn HS, Radinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, et al. Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci 2010;123: 2576-85.
167. Tumova M, Koffer A, Simicek M, Draberova L, Draber P. The transmembrane adaptor protein NTAL signals to mast cell cytoskeleton via the small GTPase Rho. Eur J Immunol 2010;40:3235-45.
168. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol 1994;153:3717-23.
169. Sharma N, Everingham S, Ramdas B, Kapur R, Craig AW. SHP2 phosphatase promotes mast cell chemotaxis toward stem cell factor via enhancing activation of the Lyn/Vav/Rac signaling axis. J Immunol 2014;192:4859-66.
170. Collington SJ, Hallgren J, Pease JE, Jones TG, Rollins BJ, Westwick J, et al. The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J Immunol 2010;184:6114-23.
171. Juremalm M, Nilsson G. Chemokine receptor expression by mast cells. Chem Immunol Allergy 2005;87:130-44.
172. Weller CL, Collington SJ, Brown JK, Miller HR, Al-Kashi A, Clark P, et al. Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J Exp Med 2005;201:1961-71.
173. Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, et al. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci U S A 2007;104:11712-7.
174. Pietrzak A, Misiak-Tloczek A, Brzezinska-Blaszczyk E. Interleukin (IL)-10 inhibits RANTES-, tumour necrosis factor (TNF)- and nerve growth factor (NGF)-induced mast cell migratory response but is not a mast cell chemoattractant. Immunol Lett 2009;123:46-51.
175. Alcaide P, Jones TG, Lord GM, Glimcher LH, Hallgren J, Arinobu Y, et al. Dendritic cell expression of the transcription factor T-bet regulates mast cell progenitor homing to mucosal tissue. J Exp Med 2007;204:431-9.
176. Eady RA, Cowen T, Marshall TF, Plummer V, Greaves MW. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol 1979;100:623-33.
177. Feger F, Varadaradjalou S, Gao Z, Abraham SN, Arock M. The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol 2002;23:151-8.

178. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SN. Phagocytic and tumor necrosis factor a response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect Immun 1998;66:6030-4.
179. Abel J, Goldmann O, Ziegler C, Holtje C, Smeltzer MS, Cheung AL, et al. *Staphylococcus aureus* evades the extracellular antimicrobial activity of mast cells by promoting its own uptake. J Innate Immun 2011;3:495-507.
180. Goldmann O, Tuchscherr L, Rohde M, Medina E. α-Hemolysin enhances *Staphylococcus aureus* internalization and survival within mast cells by modulating the expression of β1 integrin. Cell Microbiol 2016;18:807-19.
181. Trevisan E, Vita F, Medic N, Soranzo MR, Zabucchi G, Borelli V. Mast cells kill *Candida albicans* in the extracellular environment but spare ingested fungi from death. Inflammation 2014;37:2174-89.
182. Pinke KH, Lima HG, Cunha FQ, Lara VS. Mast cells phagocyte *Candida albicans* and produce nitric oxide by mechanisms involving TLR2 and Dectin-1. Immunobiology 2016;221:220-7.
183. Mollerherm H, von Kockritz-Blickwede M, Branitzki-Heinemann K. Antimicrobial activity of mast cells: role and relevance of extracellular DNA traps. Front Immunol 2016;7:265.
184. Brown JK, Donaldson DS, Wright SH, Miller HR. Mucosal mast cells and nematode infection: strain-specific differences in mast cell precursor frequency revisited. J Helminthol 2003;77:155-61.
185. Woodbury RG, Miller HR, Huntley JF, Newlands GF, Palliser AC, Wakelin D. Mucosal mast cells are functionally active during spontaneous expulsion of intestinal nematode infections in rat. Nature 1984;312:450-2.
186. Maruyama H, Yabu Y, Yoshida A, Nawa Y, Ohta N. A role of mast cell glycosaminoglycans for the immunological expulsion of intestinal nematode, *Strongyloides venezuelensis*. J Immunol 2000;164:3749-54.
187. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75-7.
188. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 1996;381:77-80.
189. Brown MA, Hatfield JK, Walker ME, Sayed BA. A game of kit and mouse: the Kit is still in the bag. Immunity 2012;36:891-2, author reply 893-4.
190. Piliponsky AM, Chen CC, Grimbaldeston MA, Burns-Guydish SM, Hardy J, Kalesnikoff J, et al. Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. Am J Pathol 2010;176:926-38.
191. Bischoff SC. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 2009;31:185-205.
192. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010;40:1843-51.
193. Bischoff SC. Mast cells in gastrointestinal disorders. Eur J Pharmacol 2016;778:139-45.
194. Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M. Mast cells as drivers of disease and therapeutic targets. Trends Immunol 2018;39:151-62.
195. Gebhardt T, Lorentz A, Detmer F, Trautwein C, Bektas H, Manns MP, et al. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor β1. Gut 2005;54:928-34.
196. Kunii J, Takahashi K, Kasakura K, Tsuda M, Nakano K, Hosono A, et al. Commensal bacteria promote migration of mast cells into the intestine. Immunobiology 2011;216:692-7.
197. Kasakura K, Takahashi K, Itoh T, Hosono A, Momose Y, Itoh K, et al. Commensal bacteria directly suppress in vitro degranulation of mast cells in a MyD88-independent manner. Biosci Biotechnol Biochem 2014;78:1669-76.
198. Jacob C, Yang PC, Darmoul D, Amadesi S, Saito T, Cottrell GS, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and β-arrestins. J Biol Chem 2005;280:31936-48.
199. Vanuytsel T, van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S, Houben E, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014;63:1293-9.
200. Kennelly R, Conneely JB, Bouchier-Hayes D, Winter DC. Mast cells in tissue healing: from skin to the gastrointestinal tract. Curr Pharm Des 2011;17:3772-5.
201. Mierke CT, Ballmaier M, Werner U, Manns MP, Welte K, Bischoff SC. Human endothelial cells regulate survival and proliferation of human mast cells. J Exp Med 2000;192:801-11.